Zentalis Pharmaceuticals (ZNTL) Competitors $1.27 +0.08 (+6.72%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.30 +0.03 (+2.36%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZNTL vs. PRTA, TERN, PRME, HUMA, AQST, SNDL, HRTX, AURA, ALT, and CTORShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), Aquestive Therapeutics (AQST), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Altimmune (ALT), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Its Competitors Prothena Terns Pharmaceuticals Prime Medicine Humacyte Aquestive Therapeutics SNDL Heron Therapeutics Aura Biosciences Altimmune Citius Oncology Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Which has stronger earnings & valuation, ZNTL or PRTA? Prothena has higher revenue and earnings than Zentalis Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZentalis Pharmaceuticals$67.43M1.36-$165.84M-$3.13-0.41Prothena$135.16M2.60-$122.31M-$2.08-3.13 Do analysts prefer ZNTL or PRTA? Zentalis Pharmaceuticals presently has a consensus price target of $8.37, indicating a potential upside of 558.79%. Prothena has a consensus price target of $31.50, indicating a potential upside of 383.13%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zentalis Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor ZNTL or PRTA? In the previous week, Prothena had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 1 mentions for Prothena and 0 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.00 beat Prothena's score of -0.16 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Zentalis Pharmaceuticals Neutral Prothena Neutral Is ZNTL or PRTA more profitable? Zentalis Pharmaceuticals has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Prothena's return on equity of -21.61% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Zentalis PharmaceuticalsN/A -65.48% -51.05% Prothena -79.94%-21.61%-19.32% Do insiders & institutionals believe in ZNTL or PRTA? 97.1% of Prothena shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ZNTL or PRTA? Zentalis Pharmaceuticals has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. SummaryProthena beats Zentalis Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.62M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-0.4120.8026.9720.11Price / Sales1.36286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book0.277.487.985.56Net Income-$165.84M-$55.04M$3.16B$248.40M7 Day Performance2.42%2.44%2.36%4.67%1 Month Performance-14.77%1.90%2.15%6.64%1 Year Performance-69.98%4.35%33.78%21.31% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals1.555 of 5 stars$1.27+6.7%$8.37+558.8%-69.6%$85.62M$67.43M-0.41160PRTAProthena3.0445 of 5 stars$6.07-0.2%$31.50+418.9%-67.7%$326.75M$135.16M-2.92130TERNTerns Pharmaceuticals3.7045 of 5 stars$3.73-2.6%$15.63+318.9%-39.8%$325.78MN/A-3.4240PRMEPrime Medicine4.0534 of 5 stars$2.47+2.1%$10.08+308.2%-25.3%$324.30M$3.85M-1.20234Options VolumeHigh Trading VolumeHUMAHumacyte2.749 of 5 stars$2.09-1.4%$11.71+460.5%-54.7%$324.20M$1.57M-3.03150News CoverageGap UpAQSTAquestive Therapeutics1.2446 of 5 stars$3.31+1.8%$10.14+206.4%+53.3%$322.82M$54.23M-5.61160SNDLSNDL3.513 of 5 stars$1.21-1.6%$3.63+199.6%-29.9%$317.96M$671.81M-4.172,516HRTXHeron Therapeutics3.8245 of 5 stars$2.07-3.3%$5.00+141.5%-25.9%$315.80M$144.29M-34.50300Positive NewsAURAAura Biosciences1.8841 of 5 stars$6.26-0.3%$22.00+251.4%-14.6%$314.69MN/A-3.2950Positive NewsALTAltimmune2.22 of 5 stars$3.87+10.6%$19.00+391.0%-33.5%$313.90M$20K-3.0750Gap DownHigh Trading VolumeCTORCitius Oncology0.3975 of 5 stars$4.35-3.3%$3.00-31.0%N/A$311.24MN/A0.00N/A Related Companies and Tools Related Companies PRTA Competitors TERN Competitors PRME Competitors HUMA Competitors AQST Competitors SNDL Competitors HRTX Competitors AURA Competitors ALT Competitors CTOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZNTL) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
